RENN, Renren Inc.

** RENN reported the release of its customized high-definition client application (?Renren HD?) for Microsoft?s Windows 8 application store.

Released at the Windows 8 Consumer Preview Conference held recently during the Mobile World Congress 2012 in Barcelona, Spain, Renren HD is the first social networking application selected by Microsoft.

Renren HD is designed to be fully-integrated with Windows 8, a generational change on Microsoft's flagship operating system. Through "share contract", a range of content from different applications can be shared at a single click, including web pages, pictures and videos.

Customized for Windows 8, which focuses on integration with social networks and optimized for tablet usage, Renren HD has adopted features such as tiled Metro-style user interfaces and creative content delivery, resulting in a significantly enhanced user experience.

RENN operates the leading real name social networking internet platform in China. RENN enables users to connect and communicate with each other, share information and user generated content, play online games, listen to music, shop for deals and enjoy a wide range of other features and services.

More about RENN at www.renren-inc.com

**********

ARNA, Arena Pharmaceuticals, Inc.

** ARNA reported the filing of a Marketing Authorization Application with the European Medicines Agency for lorcaserin, an investigational drug candidate intended for weight control, including weight loss and maintenance of weight loss, in patients who are obese (BMI >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition.

ARNA expects the EMA will accept the filing later this month and confirm the filing is sufficiently complete to permit a substantive review.

Lorcaserin is a new chemical entity that is believed to act as a selective serotonin 2C receptor agonist. The serotonin 2C receptor is expressed in the brain, including the hypothalamus, an area believed to be involved in the control of appetite and metabolism.

ARNA has patents that cover lorcaserin in the United States, major European countries and other jurisdictions that in most cases are capable of continuing into 2023 without taking into account any patent term extensions or other exclusivity ARNA might obtain.

ARNA is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.

More about ARNA at www.arenapharm.com

**********

KTOS, Kratos Defense & Security Solutions Inc.

** KTOS reported that its Herley EW Simulation Technology Ltd. (EWST) subsidiary has received a single award contract valued at $9.4 million from an international customer for the supply of two of Herley EWST's highly successful RSS8000 Radar Threat Simulator products.

The RSS8000 systems will augment a previously supplied RSS8000 system for this certain international customer's aircraft program.

KTOS is a specialized National Security technology business providing mission critical products, services and solutions for United States National Security priorities.

More about KTOS at www.KratosDefense.com.

********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.